
MOOD
Depression and so-called “bipolar” disorders are frequently treated as fixed diagnostic categories. This includes both major depressive disorder and bipolar disorder as they are currently defined. In practice, mood exists on a spectrum. It is a regulatory pattern unfolding across time. It may cycle. It may become chronically dysregulated. Stability erodes and rebuilds — sometimes repeatedly.
Some individuals experience discrete episodes separated by recovery. Others live inside prolonged major depressive episodes lasting years. Still others cycle between states. These patterns differ in appearance, but they share regulatory underpinnings.
Mood presentations are often mischaracterized.

For many individuals, what appears to be “recurrent depression” reflects an underlying mood spectrum pattern in which cyclicity — not symptom intensity alone — is the defining feature.
Mixity: Depression With Activation
Even in the absence of classic DSM hypomania, mixity is often the signal.
By mixity, I mean depressive states that contain activation:
-
Irritability that feels sharp, disproportionate, or out of character
-
Inner agitation or motor restlessness
-
Crowded, accelerated, or pressured thoughts
-
Impulsivity or increased reactivity
-
A driven, energized, or dysphoric push — sometimes meeting full hypomanic thresholds, sometimes falling just short
What makes it “mixed” is the co-occurrence of depressive symptoms with activation.
Depression with real fire in it.
The anxiety in these states is not simple rumination. It is physiologic — buzzy, electric, intolerable. It often drives insomnia. It sharpens irritability. It reflects excitatory activation rather than ordinary worry.
That activated quality is a clinical clue.
Cyclicity and Antidepressant Destabilization
When depressions recur at intervals of two years or less, or contain mixed features, I evaluate for instability in excitatory regulatory systems. Glutamatergic signaling governs cortical plasticity and tempo. When poorly regulated, it may accelerate cycling or intensify dysregulation.
Antidepressants increase excitatory signaling. In some individuals they relieve symptoms briefly. In others they produce no meaningful improvement. In still others they worsen instability — producing dysphoria, agitation, driven insomnia, suicidal activation, mood drop, or shifts toward hypomania. Sometimes lack of response and activation occur simultaneously.
Early response itself can be informative. Rapid improvement may reflect accelerated plasticity in excitatory systems. The same acceleration can later underlie loss of effectiveness over time, sometimes called tachyphylaxis or “Prozac poop-out.”
When activation emerges — particularly driven insomnia with buzzy anxiety, irritability layered onto depression, or suicidal activation — this represents instability. If there is partial symptom relief in that context, it does not equal stabilization. Antidepressants were designed to lift episodes, not to provide durable prophylaxis. Used chronically without mechanistic clarity, they may perpetuate dysregulation rather than resolve it.
Chronic Depression Still Has Drivers
Not all individuals cycle. Some present with chronic depression — longstanding low hedonic tone, persistent dysthymia, enduring major depressive episodes, or treatment-resistant unipolar MDD. In my practice, these are rarely uncomplicated first episodes. They are often chronic because underlying drivers were never clarified.
Most individuals I evaluate do not fit neatly into a single DSM label. Instead, they present with layered phenotypes:
-
Depressive episodes containing agitation or activation
-
Physiologic, electric anxiety embedded within low mood
-
Periods of increased drive, sharpened focus, or intensified irritability that alter functioning — either within depression or between episodes
-
Seasonal or equinox-linked switches
-
Postpartum depression or psychosis
-
Atypical features — sleeping excessively, increased appetite, heightened rejection sensitivity, or heavy, leaden limb fatigue (like dragging oneself up the stairs)
-
Recurrent episodes despite antidepressant trials of adequate dose and duration
-
Antidepressant-induced agitation, driven insomnia, mood drop, suicidal ideation, or activation
-
Loss of medication effectiveness over time, through tachyphylaxis, or oppositional tolerance
-
Chronic, unremitting depression in which biological drivers were never fully assessed
These patterns are better understood dimensionally rather than categorically.
How I Evaluate Complex Mood Presentations
Evaluation prioritizes pattern recognition.
Assessment examines:
-
Cyclicity and tempo
-
Episode spacing across years
-
Neurovegetative shifts including sleep architecture, energy, appetite, libido, and psychomotor change
-
Family loading for mood spectrum illness
-
Antidepressant-associated activation or destabilization
-
Seasonality or postpartum onset
-
Baseline physiologic anxiety or irritability
-
Breakthrough episodes or tachyphylaxis
-
Medical, inflammatory, endocrine, metabolic, and circadian contributors
-
And so much more

Mechanistic Formulation and Durable Stabilization
DSM diagnosis is descriptive, operational, and largely atheoretical. My formulation is mechanistic. It integrates symptoms, longitudinal history, biological correlates, and classical mood spectrum literature extending from Kraepelin through modern dimensional models. Top-down labeling describes. Bottom-up formulation clarifies drivers.
Treatment must be mechanistic.
Durable stabilization is foundational.
Mood instability or chronicity reflects dysregulation across interacting systems: sleep–wake architecture, circadian timing, inflammatory signaling, endocrine modulation, stress physiology, and excitatory–inhibitory balance within cortical circuits.
With each untreated or poorly stabilized episode, neural networks may consolidate the current state. Plasticity strengthens the grooves of that pattern. The system can become easier to trigger and harder to interrupt.
Stabilization interrupts that process.
The goal is not short-term symptom suppression.
The goal is sustained regulation — cognitive clarity, emotional range without volatility, intact executive function, and resilience across seasons and stressors.
Antidepressant Strategy
Although reuptake inhibitors are commonly positioned as first-line options in many treatment guidelines, they are not universally benign and may, in certain patients, contribute to emotional blunting, activation, sleep disruption, or mood instability over time.
For this reason, I do not approach antidepressants as reflexive solutions. Treatment decisions are guided by longitudinal patterning, cyclicity, excitatory–inhibitory balance, and the goal of durable stabilization rather than short-term symptom suppression.
If a patient is already stable and clearly benefiting from a medication, I do not reflexively discontinue it. All prescribing decisions prioritize long-term physiologic stewardship, functional clarity, and risk containment.
A detailed educational guide on antidepressant risks and tapering considerations is available upon request for patients who wish to review the literature in greater depth.
Second-Generation Antipsychotics
Second-generation antipsychotics can be powerful tools for acute stabilization when clearly indicated. I use them strategically and time-limited when possible, with careful attention to metabolic, endocrine, and neurologic burden.
Long-term exposure is not treated as benign. Ongoing need is reassessed regularly, with preference for the lowest effective dose and strategies that preserve glycemic stability, minimize prolactin elevation, and protect cognitive function.
The goal is durable stabilization without unnecessary physiologic cost.
On Antidepressant and Antipsychotic Tapers
For individuals whose prior strategies have contributed to instability or side effects, I provide supported tapers. Tapering is deliberate, gradual, and physiologically informed — not abrupt.
In bipolar disorder, psychotic depression, or severe agitation, antipsychotics may play an essential role in achieving safety and stability.
This Page Will Continue to Expand
-
Mood spectrum and mixed presentations
-
Antidepressant destabilization
-
Treatment-resistant depression re-examined
-
Neuroprogression and episode consolidation
-
Stability as a primary treatment target
-
Dimensional models of regulation
Mood is not a static diagnosis.
It is a regulatory pattern.
Patterns can be clarified — and stabilized.